Safety and Efficacy of Denosumab in Children With Osteogenesis Imperfecta—the First Prospective Comparative Study
The Journal of Clinical Endocrinology & Metabolism · 17.06.2024 · 109 (7) · 1827-1836
DOI: 10.1210/clinem/dgad732 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 10.01.2024. Verfasst von Jiayi Liu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Key Laboratory of Endocrinology, National Health and Family Planning Commission, Peking Union Medical College Hospital, …. Hauptthemen laut MEDLINE: Denosumab, Osteogenesis Imperfecta, Bone Density, Bone Density Conservation Agents. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, National High Level Hospital Clinical Research Funding.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Context
Denosumab is a potential therapeutic agent for osteogenesis imperfecta (OI), but its efficacy and safety remain unclear in children with OI.
Objective
We aimed to investigate the effects of denosumab on bone mineral density (BMD), spinal morphometry, and safety in children with OI compared with zoledronic acid.
Methods
In this prospective study, 84 children or adolescents with OI were randomized to receive denosumab subcutaneous injection every 6 months or zoledronic acid intravenous infusion once. Changes of BMD and its Z-score, vertebral shape, serum levels of calcium and bone turnover biomarkers were assessed during the 1-year treatment.
Results
After 12 months of treatment, BMD at the lumbar spine, femoral neck, and total hip significantly increased by 29.3%, 27.8%, and 30.2% in the denosumab group, and by 32.2%, 47.1%, and 41.1% in the zoledronic acid group (all P < .001 vs baseline). Vertebral height and projection area significantly increased after denosumab and zoledronic acid treatment. Rebound hypercalcemia was found to be a common and serious side effect of denosumab, of which 14.3% reached hypercalcemic crisis. Rebound hypercalcemia could be alleviated by switching to zoledronic acid treatment.
Conclusion
Treatment with denosumab or zoledronic acid is beneficial in increasing BMD and improving the spinal morphometry of children with OI. However, denosumab should be used with caution in pediatric patients with OI because of its common and dangerous side effect of rebound hypercalcemia. The appropriate dosage and dosing interval of denosumab need to be further explored in children with OI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology, Key Laboratory of Endocrinology, National Health and Family Planning Commission, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College,…
Förderung
- National Natural Science Foundation of China
- National High Level Hospital Clinical Research Funding
Zitieren
APA
Liu, J., Lin, X., Sun, L., Zhang, Q., Jiang, Y., Wang, O., Xing, X., Xia, W., & Li, M. (2024). Safety and Efficacy of Denosumab in Children With Osteogenesis Imperfecta—the First Prospective Comparative Study. The Journal of Clinical Endocrinology & Metabolism, 109(7), 1827-1836. https://doi.org/10.1210/clinem/dgad732
Vancouver
Liu J, Lin X, Sun L, Zhang Q, Jiang Y, Wang O, et al. Safety and Efficacy of Denosumab in Children With Osteogenesis Imperfecta—the First Prospective Comparative Study. The Journal of Clinical Endocrinology & Metabolism. 2024;109(7):1827-1836. doi:10.1210/clinem/dgad732
BibTeX
@article{Liu2024,
author = {Liu, Jiayi and Lin, Xiaoyun and Sun, Lei and Zhang, Qian and Jiang, Yan and Wang, Ou and Xing, Xiaoping and Xia, Weibo and Li, Mei},
title = {Safety and Efficacy of Denosumab in Children With Osteogenesis Imperfecta—the First Prospective Comparative Study},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2024},
volume = {109},
number = {7},
pages = {1827--1836},
doi = {10.1210/clinem/dgad732}
}
EUVIMED